Holen Sie sich die Stockscreener-App
93.02
6.34%
-6.30
Handel nachbörslich:
93.02
Schlusskurs vom Vortag:
$99.32
Offen:
$98.25
24-Stunden-Volumen:
717.69K
Relative Volume:
1.50
Marktkapitalisierung:
$6.20B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-23.85
EPS:
-3.9
Netto-Cashflow:
$-185.06M
1W Leistung:
-4.80%
1M Leistung:
+10.45%
6M Leistung:
+20.09%
1J Leistung:
+4.26%
1-Tages-Spanne:
$92.35
$99.81
1-Wochen-Bereich:
$92.35
$104.90
52-Wochen-Spanne:
$55.53
$104.90
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Vergleichen Sie NUVL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
93.02 | 7.22B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
How risky is Nuvalent Inc. stock now2025 Volume Leaders & Verified Momentum Stock Watchlist - newser.com
Can Nuvalent Inc. stock outperform in 2025 bull market2025 Retail Activity & Reliable Trade Execution Plans - newser.com
Why Nuvalent Inc. stock remains resilientJuly 2025 Market Mood & Target Return Focused Picks - newser.com
How Nuvalent Inc. stock trades during market volatilityEarnings Recap Summary & Daily Stock Trend Watchlist - newser.com
What momentum indicators show for Nuvalent Inc. stockTrade Ideas & Long Hold Capital Preservation Tips - newser.com
Why analysts remain bullish on Nuvalent Inc. stockMarket Weekly Review & Momentum Based Trading Ideas - newser.com
Will Nuvalent Inc. bounce back from current supportRate Hike & Weekly Setup with ROI Potential - newser.com
Statistical indicators supporting Nuvalent Inc.’s strengthWall Street Watch & Technical Entry and Exit Alerts - newser.com
Published on: 2025-11-02 23:09:14 - newser.com
What data driven models say about Nuvalent Inc.’s futureTrade Analysis Summary & Daily Oversold Stock Bounce Ideas - newser.com
Using economic indicators to assess Nuvalent Inc. potentialBond Market & Real-Time Stock Price Movement Reports - newser.com
Will Nuvalent Inc. stock rally after Fed decisions2025 Market Trends & Low Drawdown Trading Techniques - newser.com
Custom strategy builders for tracking Nuvalent Inc.2025 Market Overview & Real-Time Volume Analysis - newser.com
Can volume confirm reversal in Nuvalent Inc.2025 Technical Overview & Community Consensus Picks - newser.com
Nuvalent, Inc. Reports Q3 2025 Progress and Financials - MSN
Published on: 2025-11-02 03:40:29 - newser.com
Barclays Maintains Nuvalent (NUVL) Overweight Recommendation - MSN
Nuvalent (NASDAQ:NUVL) Insider Deborah Ann Miller Sells 21,800 Shares - MarketBeat
Applying sector rotation models to Nuvalent Inc.Weekly Trading Summary & Pattern Based Trade Signal System - newser.com
Piper Sandler Maintains Nuvalent (NUVL) Overweight Recommendation - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Centene (CNC) and Nuvalent (NUVL) - The Globe and Mail
Nuvalent Inc Reports Q3 2025 EPS of -$1.70, Missing Estimates; S - GuruFocus
What moving averages say about Nuvalent Inc.July 2025 Update & Breakout Confirmation Trade Signals - newser.com
Nuvalent price target raised to $132 from $114 at UBS - MSN
Nuvalent price target raised to $120 from $105 at Goldman Sachs - TipRanks
Nuvalent (NASDAQ:NUVL) Announces Earnings Results - MarketBeat
Barclays Raises Price Target for Nuvalent (NUVL) to $112.00 | NU - GuruFocus
Nuvalent Executives Sell Shares Under Trading Plans - TradingView
NUVL insider trades: 4,000 options exercised, 4,000 shares sold - Stock Titan
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
UBS Adjusts Price Target on Nuvalent to $132 From $114, Maintains Buy Rating - MarketScreener
Nuvalent stock price target raised to $132 by UBS on cancer drug progress - Investing.com Canada
Analysts Are Bullish on Top Healthcare Stocks: TransMedics Group (TMDX), Nuvalent (NUVL) - The Globe and Mail
Why Nuvalent Inc. stock is trending among retail traders2025 Investor Takeaways & Growth Focused Stock Pick Reports - newser.com
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight - GuruFocus
Insider Selling: Nuvalent (NASDAQ:NUVL) Director Sells $1,437,799.35 in Stock - MarketBeat
Insider Selling: Nuvalent (NASDAQ:NUVL) Director Sells 32,455 Shares of Stock - MarketBeat
Nuvalent, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
FY2026 EPS Estimates for Nuvalent Decreased by Analyst - MarketBeat
Nuvalent’s Cash Cushion Keeps Investors On Board Through Setbacks - Finimize
Nuvalent Q3 Net Loss Widens - MarketScreener
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results - The Malaysian Reserve
Biopharma firm Nuvalent's Q3 net loss widens - MarketScreener
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):